<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10537">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653861</url>
  </required_header>
  <id_info>
    <org_study_id>JULIDO-001</org_study_id>
    <nct_id>NCT00653861</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and effectiveness of JUVÉDERM™ Injectable Gel with Lidocaine compared to JUVÉDERM™
      without Lidocaine for procedural pain in the treatment of nasolabial folds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlled, randomized, split-face study in which subjects receive JUVÉDERM™ Injectable Gel
      with Lidocaine (Ultra or Ultra Plus) in one nasolabial fold and JUVÉDERM™ Injectable Gel
      without Lidocaine (Ultra or Ultra Plus) in the other nasolabial fold. The investigator
      determines whether the subject receives JUVÉDERM™ Ultra or Ultra Plus per the level of
      correction desired; the lidocaine assignment is randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Procedural Pain Score</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate pain on an 11-point scale, where 0 is no pain and 10 is the worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative Pain</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 5-point scale (-2 = Right NLF more painful than Left NLF; -1 = Right NLF slightly more painful than Left NLF; 0 = No difference; 1 = Left NLF slightly more painful than Right NLF; 2 = Left NLF more painful than Right NLF). Subjects selected one category from the scale; the percentage of subjects that selected each category is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasolabial Fold (NLF) Severity</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of improvement in NLF severity score on 5-point NLF Severity Scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Extreme) two weeks after treatment with Juvederm with Lidocaine (either Ultra or Ultra Plus) in one nasolabial fold and Juvederm (either Ultra or Ultra Plus) in the other nasolabial fold.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Juvederm with Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvederm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM™ Injectable Gel with Lidocaine</intervention_name>
    <description>Single treatment, volume determined by investigator</description>
    <arm_group_label>Juvederm with Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM™ Injectable Gel</intervention_name>
    <description>Single treatment, volume determined by investigator</description>
    <arm_group_label>Juvederm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female, 18 years of age or older

          -  Desire correction of moderate to severe nasolabial folds (NLFs)

          -  Have approximately symmetrical NLFs, i.e., both NLFs have the same pretreatment NLF
             severity score

        Exclusion Criteria:

          -  Have undergone cosmetic facial procedures in the lower 2/3 of the face within 1 month
             prior to entry in the study or are planning to undergo these procedure during the
             study.

          -  Begin use of any new over-the-counter or prescription, oral or topical, anti-wrinkle
             products in the NLF area within 1 month prior to enrollment or are planning to begin
             use of such products during the study.

          -  Have undergone previous hyaluronic acid (HA)-based dermal filler treatments such that
             the total volume of HA injected within 12 months prior to study entry is within 5 mL
             of the recommended annual maximum volume for HA dermal fillers.

          -  Has ever received semi-permanent fillers or permanent facial implants anywhere in the
             face or neck, or is planning to be implanted with these products during the study.

          -  Have a history of anaphylaxis, multiple severe allergies, atopy, or allergy to
             lidocaine (or any amide-based anesthetic), hyaluronic acid products, or Streptococcal
             protein, or have plans to undergo desensitization therapy during the term of the
             study.

          -  Have an active inflammation, infection, cancerous or pre-cancerous lesion, or
             unhealed wound in the NLF area
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mt. Kisco</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juvéderm injectable gel with and without lidocaine. J Cosmet Dermatol. 2009 Sep;8(3):205-10. doi: 10.1111/j.1473-2165.2009.00451.x.</citation>
    <PMID>19735519</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>October 6, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2008</firstreceived_date>
  <firstreceived_results_date>July 22, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aesthetic correction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Other aesthetic procedures and products were not allowed 1 month prior to study entry or any time during the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Study Participants</title>
          <description>Subjects who received Juvederm with Lidocaine in one nasolabial fold and Juvederm without Lidocaine in the other nasolabial fold</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study Participants</title>
          <description>Subjects who received Juvéderm with Lidocaine in one nasolabial fold and Juvéderm without Lidocaine in the other nasolabial fold.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.9" spread="9.03"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedural Pain Score</title>
        <description>Evaluate pain on an 11-point scale, where 0 is no pain and 10 is the worst pain imaginable.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm Lidocaine Nasolabial Folds (NLFs)</title>
            <description>Nasolabial folds on one side of the face injected with the Juvederm formulation with lidocaine</description>
          </group>
          <group group_id="O2">
            <title>Juvéderm Nasolabial Folds (NLFs)</title>
            <description>Nasolabial folds on the corresponding side of the face injected with Juvederm</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Procedural Pain Score</title>
            <description>Evaluate pain on an 11-point scale, where 0 is no pain and 10 is the worst pain imaginable.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="1.71"/>
                  <measurement group_id="O2" value="5.4" spread="2.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative Pain</title>
        <description>A 5-point scale (-2 = Right NLF more painful than Left NLF; -1 = Right NLF slightly more painful than Left NLF; 0 = No difference; 1 = Left NLF slightly more painful than Right NLF; 2 = Left NLF more painful than Right NLF). Subjects selected one category from the scale; the percentage of subjects that selected each category is presented.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Participants</title>
            <description>Subjects who received Juvéderm with Lidocaine in one nasolabial fold and Juvéderm without Lidocaine in the other nasolabial fold.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comparative Pain</title>
            <description>A 5-point scale (-2 = Right NLF more painful than Left NLF; -1 = Right NLF slightly more painful than Left NLF; 0 = No difference; 1 = Left NLF slightly more painful than Right NLF; 2 = Left NLF more painful than Right NLF). Subjects selected one category from the scale; the percentage of subjects that selected each category is presented.</description>
            <units>Percent of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Juvéderm Lidocaine is Less Painful than Juvéderm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Juvéderm Lidocaine is Slightly Less Painful</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Difference</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Juvéderm Lidocaine is Slightly More Painful</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Juvéderm Lidocaine is More Painful than Juvéderm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasolabial Fold (NLF) Severity</title>
        <description>Determination of improvement in NLF severity score on 5-point NLF Severity Scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Extreme) two weeks after treatment with Juvederm with Lidocaine (either Ultra or Ultra Plus) in one nasolabial fold and Juvederm (either Ultra or Ultra Plus) in the other nasolabial fold.</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm Lidocaine NLFs</title>
            <description>Nasolabial folds on one side of the face injected with the Juvederm formulation with lidocaine</description>
          </group>
          <group group_id="O2">
            <title>Juvéderm NLFs</title>
            <description>Nasolabial folds on the corresponding side of the face injected with Juvederm</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Nasolabial Fold (NLF) Severity</title>
            <description>Determination of improvement in NLF severity score on 5-point NLF Severity Scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Extreme) two weeks after treatment with Juvederm with Lidocaine (either Ultra or Ultra Plus) in one nasolabial fold and Juvederm (either Ultra or Ultra Plus) in the other nasolabial fold.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Improvement using Juvederm Ultra</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="0.60"/>
                  <measurement group_id="O2" value="1.6" spread="0.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improvement using Juvederm Ultra Plus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="0.58"/>
                  <measurement group_id="O2" value="1.8" spread="0.65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Juvéderm Lidocaine Nasolabial Folds (NLFs)</title>
          <description>Nasolabial folds on one side of the face injected with the Juvederm formulation with lidocaine</description>
        </group>
        <group group_id="E2">
          <title>Juvéderm Nasolabial Folds (NLFs)</title>
          <description>Nasolabial folds on the corresponding side of the face injected with Juvederm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection side induration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Injection site discoloration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Application site bruising</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Injection site edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least ninety (90) days prior to any proposed submission for publication or presentation of Study data or other findings related to the Study, the Investigator will provide the Sponsor with a manuscript of such submission(s) for review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan Medical</organization>
      <phone>(805) 961-5500</phone>
      <email>devicetrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
